CLL with TP53 mutation without the 17p deletion shows similar outcome as CLL with the 17p deletion after first-line F-based therapy (CLL4 trial of the GCLLSG). OS of the group with the 17p deletion (n = 16) is shown in red; OS of the sole TP53 mutation without the 17p deletion (n = 14) is shown in black; and the OS of remaining patients (n = 277) is shown in green. Median OS was significantly shorter for patients with the 17p deletion (19.2 months) and sole TP53 mutation (30.2 months) compared with patients without either abnormality (median not reached; p < 0.001). (Data from ²³ .)